A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

NCT01705236 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis RRMS

Interventions

DRUG: Fingolimod

Sponsor

Novartis Pharmaceuticals